TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II Trial of Docetaxel Plus Oxaliplatin (DOCOX) With or Without Cetuximab in Patients With Metastatic Gastric and/or Gastroesophageal Junction Adenocarcinoma
Brief Summary: The purpose of this research study is to find out what effects (good and bad) docetaxel, oxaliplatin, and cetuximab have on gastric or GEJ cancer.


Options:
A: Arm Label: TE (Taxotere and Eloxatin); Type: EXPERIMENTAL; Interventions: Drug: Docetaxel + Oxaliplatin | Arm Label: TEF (Taxotere, Eloxatin and 5-FU); Type: EXPERIMENTAL; Interventions: Drug: Docetaxel + Oxaliplatin + 5-FU | Arm Label: TEX (Taxotere, Eloxatin and Xeloda); Type: EXPERIMENTAL; Interventions: Drug: Docetaxel + Oxaliplatin + Capecitabine | Intervention Type: DRUG; Name: Docetaxel + Oxaliplatin; Assigned to Arm(s): TE (Taxotere and Eloxatin) | Intervention Type: DRUG; Name: Docetaxel + Oxaliplatin + 5-FU; Assigned to Arm(s): TEF (Taxotere, Eloxatin and 5-FU) | Intervention Type: DRUG; Name: Docetaxel + Oxaliplatin + Capecitabine; Assigned to Arm(s): TEX (Taxotere, Eloxatin and Xeloda)
B: Arm Label: 1- Docetaxel plus Oxaliplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel, Drug: oxaliplatin | Arm Label: 2- Docetaxel plus oxaliplatin plus cetuximab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel, Drug: cetuximab, Drug: oxaliplatin | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): 1- Docetaxel plus Oxaliplatin, 2- Docetaxel plus oxaliplatin plus cetuximab | Intervention Type: DRUG; Name: cetuximab; Assigned to Arm(s): 2- Docetaxel plus oxaliplatin plus cetuximab | Intervention Type: DRUG; Name: oxaliplatin; Assigned to Arm(s): 1- Docetaxel plus Oxaliplatin, 2- Docetaxel plus oxaliplatin plus cetuximab
C: Arm Label: Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Capecitabine, Drug: Cisplatin, Drug: 5-fluorouracil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Capecitabine, Drug: Cisplatin, Drug: Placebo, Drug: 5-fluorouracil | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Bevacizumab | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Bevacizumab, Placebo | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Bevacizumab, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: 5-fluorouracil; Assigned to Arm(s): Bevacizumab, Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Docetaxel, Drug: 5-Fluorouracil, Drug: Oxaliplatin, Drug: folinic acid | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: 5-Fluorouracil, Drug: Oxaliplatin, Drug: folinic acid | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: 5-Fluorouracil; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Oxaliplatin; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: folinic acid; Assigned to Arm(s): 1, 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II Trial of Docetaxel Plus Oxaliplatin (DOCOX) With or Without Cetuximab in Patients With Metastatic Gastric and/or Gastroesophageal Junction Adenocarcinoma
Brief Summary: The purpose of this research study is to find out what effects (good and bad) docetaxel, oxaliplatin, and cetuximab have on gastric or GEJ cancer.


Options:
A: Arm Label: Arm A EOX; Type: ACTIVE_COMPARATOR; Interventions: Drug: epirubicin, oxaliplatin, capecitabine (EOX) | Arm Label: Arm B EOX + panitumumab.; Type: ACTIVE_COMPARATOR; Interventions: Drug: EOX + panitumumab | Intervention Type: DRUG; Name: epirubicin, oxaliplatin, capecitabine (EOX); Assigned to Arm(s): Arm A EOX | Intervention Type: DRUG; Name: EOX + panitumumab; Assigned to Arm(s): Arm B EOX + panitumumab.
B: Arm Label: 1- Docetaxel plus Oxaliplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel, Drug: oxaliplatin | Arm Label: 2- Docetaxel plus oxaliplatin plus cetuximab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel, Drug: cetuximab, Drug: oxaliplatin | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): 1- Docetaxel plus Oxaliplatin, 2- Docetaxel plus oxaliplatin plus cetuximab | Intervention Type: DRUG; Name: cetuximab; Assigned to Arm(s): 2- Docetaxel plus oxaliplatin plus cetuximab | Intervention Type: DRUG; Name: oxaliplatin; Assigned to Arm(s): 1- Docetaxel plus Oxaliplatin, 2- Docetaxel plus oxaliplatin plus cetuximab
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: TS-1 (S-1) | Arm Label: 2; Type: OTHER; Interventions: Procedure: Surgery | Intervention Type: DRUG; Name: TS-1 (S-1); Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Surgery; Assigned to Arm(s): 2
D: Arm Label: Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Capecitabine, Drug: Cisplatin, Drug: 5-fluorouracil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Capecitabine, Drug: Cisplatin, Drug: Placebo, Drug: 5-fluorouracil | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Bevacizumab | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Bevacizumab, Placebo | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Bevacizumab, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: 5-fluorouracil; Assigned to Arm(s): Bevacizumab, Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis
Brief Summary: Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease that affects an individual's ability to breathe. This study will evaluate the effectiveness of sildenafil, a medication that increases blood flow to the lungs, at improving breathing function, exercise capacity, and quality of life in people with advanced IPF.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Selexipag | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Selexipag; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: Sildenafil; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sildenafil Citrate | Arm Label: Placebo / Sildanafil; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Sildenafil Citrate; Assigned to Arm(s): Sildenafil | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo / Sildanafil
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Riociguat (Adempas, BAY63-2521) | Intervention Type: DRUG; Name: Riociguat (Adempas, BAY63-2521); Assigned to Arm(s): Arm 1
D: Arm Label: Sildenafil plus pulmonary rehabilitation; Type: EXPERIMENTAL; Interventions: Drug: Sildenafil | Arm Label: Placebo plus pulmonary rehabilitation; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Sildenafil; Assigned to Arm(s): Sildenafil plus pulmonary rehabilitation | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo plus pulmonary rehabilitation

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Finnish Diabetes Prevention Study: A Follow-up Study on the Effect of a Dietary and Exercise Intervention in the Prevention of Diabetes and Its Vascular Complications
Brief Summary: The aim of this study is to clarify whether lifestyle intervention provided to people with high type 2 diabetes risk will lower the cumulative incidence of diabetes. Furthermore, the aim is to study the effect of lifestyle intervention on cardiovascular risk.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Intensive lifestyle counselling | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Intensive lifestyle counselling; Assigned to Arm(s): 1
B: Arm Label: Lifestyle; Type: EXPERIMENTAL; Interventions: Behavioral: Group-Based Lifestyle Intervention (Phases 1 and 2), Behavioral: Self-Directed Maintenance (Phase 3), Behavioral: Extended Group Maintenance (Phase 3) | Arm Label: Comparison; Type: OTHER; Interventions: Other: Individual Education Program (All Phases) | Intervention Type: BEHAVIORAL; Name: Group-Based Lifestyle Intervention (Phases 1 and 2); Assigned to Arm(s): Lifestyle | Intervention Type: OTHER; Name: Individual Education Program (All Phases); Assigned to Arm(s): Comparison | Intervention Type: BEHAVIORAL; Name: Self-Directed Maintenance (Phase 3); Assigned to Arm(s): Lifestyle | Intervention Type: BEHAVIORAL; Name: Extended Group Maintenance (Phase 3); Assigned to Arm(s): Lifestyle
C: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Self-Management Program; Type: EXPERIMENTAL; Interventions: Behavioral: Self-management program (SM) | Arm Label: Care Management Program; Type: EXPERIMENTAL; Interventions: Behavioral: Care management program (CM) | Intervention Type: BEHAVIORAL; Name: Self-management program (SM); Assigned to Arm(s): Self-Management Program | Intervention Type: BEHAVIORAL; Name: Care management program (CM); Assigned to Arm(s): Care Management Program
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Promote and support healthy behaviors | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Promote and support healthy behaviors; Assigned to Arm(s): Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Multicenter, Double-Blind, Weight-Based, Fixed-Dose, Parallel-Group, Placebo-Controlled Study of the Efficacy and Safety of Extended Release Paliperidone for the Treatment of Schizophrenia in Adolescent Subjects, 12 to 17 Years of Age
Brief Summary: The purpose of this study is to evaluate the efficacy, safety, and tolerability of 3 weight-based, fixed-dose groups of paliperidone extended release (ER) compared with placebo in adolescent patients between 12 to 17 years of age, who are diagnosed with schizophrenia. Paliperidone ER is an atypical antipsychotic agent approved by the U.S. Food and Drug Administration for the treatment of schizophrenia in adults. Patients may be voluntary inpatients or outpatients at the time of the screening visit, but should have returned to their usual living situation by Day 21 of the double-blind treatment phase. The study duration is approximately 10 weeks. Patients who have completed this study or who were discontinued from this study due to lack of efficacy but have completed at least 21 days of double-blind treatment and are expected to benefit from paliperidone treatment, may enter an optional open-label safety study.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Brexpiprazole (OPC-34712); Type: EXPERIMENTAL; Interventions: Drug: Brexpiprazole | Intervention Type: DRUG; Name: Brexpiprazole; Assigned to Arm(s): Brexpiprazole (OPC-34712) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: Paliperidone ER | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: Paliperidone ER | Arm Label: 003; Type: EXPERIMENTAL; Interventions: Drug: Paliperidone ER | Arm Label: 004; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Paliperidone ER; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 004 | Intervention Type: DRUG; Name: Paliperidone ER; Assigned to Arm(s): 001 | Intervention Type: DRUG; Name: Paliperidone ER; Assigned to Arm(s): 003
C: Arm Label: Integrated Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Integrated Treatment | Arm Label: Community Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Community Care | Intervention Type: BEHAVIORAL; Name: Integrated Treatment; Assigned to Arm(s): Integrated Treatment | Intervention Type: BEHAVIORAL; Name: Community Care; Assigned to Arm(s): Community Care
D: Arm Label: BI 409306 dose 1; Type: EXPERIMENTAL; Interventions: Drug: BI 409306 | Arm Label: BI 409306 dose 2; Type: EXPERIMENTAL; Interventions: Drug: BI 409306 | Arm Label: BI 409306 dose 3; Type: EXPERIMENTAL; Interventions: Drug: BI 409306 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: BI 409306; Assigned to Arm(s): BI 409306 dose 1, BI 409306 dose 2, BI 409306 dose 3

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center Trial to Study Acute Liver Failure in Adults
Brief Summary: The purpose of this study is to collect clinical and epidemiological data as well as serum, plasma, urine, tissue and DNA samples on individuals who have acute liver failure and on individuals who have acute liver injury, a less severe group of patients who have coagulopathy but do not reach the threshold of encephalopathy.


Options:
A: Arm Label: Ondansetron /acetylcysteine 20.25h; Type: OTHER; Interventions: Drug: Ondansetron, Drug: acetylcysteine | Arm Label: Placebo/acetylcysteine 20.25h; Type: OTHER; Interventions: Drug: acetylcysteine | Arm Label: Ondansetron/acetylcysteine 12h; Type: OTHER; Interventions: Drug: Ondansetron, Drug: acetylcysteine | Arm Label: Placebo/acetylcysteine 12h; Type: OTHER; Interventions: Drug: acetylcysteine | Intervention Type: DRUG; Name: Ondansetron; Assigned to Arm(s): Ondansetron /acetylcysteine 20.25h, Ondansetron/acetylcysteine 12h | Intervention Type: DRUG; Name: acetylcysteine; Assigned to Arm(s): Ondansetron/acetylcysteine 12h, Placebo/acetylcysteine 12h | Intervention Type: DRUG; Name: acetylcysteine; Assigned to Arm(s): Ondansetron /acetylcysteine 20.25h, Placebo/acetylcysteine 20.25h
B: Intervention Type: DRUG; Name: acetaminophen sustained-release; Assigned to Arm(s): N/A
C: N/A
D: Intervention Type: DEVICE; Name: Molecular Adsorbent Recirculating System (MARS®); Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comprehensive Oral Care for the Intubated Neuroscience ICU Patient: A Comparison of the Safety and Efficacy Between 2 Protocols
Brief Summary: The purpose of this study is to compare how effective different ways of mouth cleaning are for patients in a neuroscience intensive care unit with a breathing tube in their mouth.


Options:
A: Arm Label: Placebo (Vehicle Control); Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: 0.12% chlorhexidine gluconate oral rinse; Type: EXPERIMENTAL; Interventions: Drug: chlorhexidine gluconate oral rinse (0.12%) | Arm Label: 0.12% chlorhexidine oral rinse; Type: EXPERIMENTAL; Interventions: Drug: chlorhexidine gluconate oral rinse (0.12%), Drug: placebo | Intervention Type: DRUG; Name: chlorhexidine gluconate oral rinse (0.12%); Assigned to Arm(s): 0.12% chlorhexidine gluconate oral rinse, 0.12% chlorhexidine oral rinse | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 0.12% chlorhexidine oral rinse, Placebo (Vehicle Control)
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard Oral Care | Arm Label: B; Type: EXPERIMENTAL; Interventions: Procedure: Comprehensive Oral Care | Intervention Type: PROCEDURE; Name: Standard Oral Care; Assigned to Arm(s): A | Intervention Type: PROCEDURE; Name: Comprehensive Oral Care; Assigned to Arm(s): B
C: Arm Label: 0.12% Chlorhexidie Digluconate; Type: EXPERIMENTAL; Interventions: Drug: 0.12% Chlorhexidine Digluconate | Arm Label: Toothbrushing; Type: PLACEBO_COMPARATOR; Interventions: Other: Toothbrushing | Intervention Type: DRUG; Name: 0.12% Chlorhexidine Digluconate; Assigned to Arm(s): 0.12% Chlorhexidie Digluconate | Intervention Type: OTHER; Name: Toothbrushing; Assigned to Arm(s): Toothbrushing
D: Intervention Type: DRUG; Name: Chlorhexidine gluconate (drug) vs placebo; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comprehensive Oral Care for the Intubated Neuroscience ICU Patient: A Comparison of the Safety and Efficacy Between 2 Protocols
Brief Summary: The purpose of this study is to compare how effective different ways of mouth cleaning are for patients in a neuroscience intensive care unit with a breathing tube in their mouth.


Options:
A: Arm Label: Pre-intubation CHX; Type: EXPERIMENTAL; Interventions: Procedure: Pre-intubation CHX | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Control | Intervention Type: PROCEDURE; Name: Pre-intubation CHX; Assigned to Arm(s): Pre-intubation CHX | Intervention Type: PROCEDURE; Name: Control; Assigned to Arm(s): Control
B: Arm Label: Toothbrushing with a manual brush; Type: EXPERIMENTAL; Interventions: Device: Toothbrushing with a manual brush | Arm Label: No toothbrushing; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Toothbrushing with a manual brush; Assigned to Arm(s): Toothbrushing with a manual brush
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard Oral Care | Arm Label: B; Type: EXPERIMENTAL; Interventions: Procedure: Comprehensive Oral Care | Intervention Type: PROCEDURE; Name: Standard Oral Care; Assigned to Arm(s): A | Intervention Type: PROCEDURE; Name: Comprehensive Oral Care; Assigned to Arm(s): B
D: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: oral hygiene | Intervention Type: OTHER; Name: oral hygiene; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): 1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Integrated Multidisciplinary Care for Parkinson's Disease: a Controlled Trial
Brief Summary: The aim of the present study is to evaluate the (cost) effectiveness of a new health care system in which an individualised multidisciplinary assessment is given to patients with Parkinson's Disease(PD)in combination with treatment by a dedicated team of specifically trained health professionals, compared to usual care. Overall, we anticipate to gain more insight in the clinical effectiveness and health care costs of multidisciplinary treatment in PD.


Options:
A: Arm Label: Virtual Reality Training; Type: EXPERIMENTAL; Interventions: Device: Balance Training with Nintendo Wii Fit | Arm Label: Physical Therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Physical Therapy | Intervention Type: DEVICE; Name: Balance Training with Nintendo Wii Fit; Assigned to Arm(s): Virtual Reality Training | Intervention Type: OTHER; Name: Physical Therapy; Assigned to Arm(s): Physical Therapy
B: Arm Label: Virtual reality based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Virtual reality based intervention | Arm Label: Conventional intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Conventional intervention | Intervention Type: BEHAVIORAL; Name: Virtual reality based intervention; Assigned to Arm(s): Virtual reality based intervention | Intervention Type: BEHAVIORAL; Name: Conventional intervention; Assigned to Arm(s): Conventional intervention
C: Arm Label: I; Type: EXPERIMENTAL; Interventions: Other: Multidisciplinary Care | Arm Label: II; Type: OTHER; Interventions: Other: Usual Care | Intervention Type: OTHER; Name: Multidisciplinary Care; Assigned to Arm(s): I | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): II
D: Arm Label: TT+VR; Type: EXPERIMENTAL; Interventions: Other: TT+VR | Arm Label: TT alone; Type: ACTIVE_COMPARATOR; Interventions: Other: TT alone | Intervention Type: OTHER; Name: TT+VR; Assigned to Arm(s): TT+VR | Intervention Type: OTHER; Name: TT alone; Assigned to Arm(s): TT alone

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Clinical Trial for the Treatment of Postnatal Depression
Brief Summary: A randomized clinical trial was carried out at primary care level in Santiago, Chile to investigate a combined treatment for women suffering post-natal depression and preventing the adverse consequences of this illness on infant's growth and development.


Options:
A: Intervention Type: DRUG; Name: Treatment of depression; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Suicide prevention intervention; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Suicide prevention treatment; Assigned to Arm(s): N/A
B: Arm Label: Arm 1; Type: OTHER; Interventions: Procedure: System level depression care quality improvement | Intervention Type: PROCEDURE; Name: System level depression care quality improvement; Assigned to Arm(s): Arm 1
C: Arm Label: PND-MCI; Type: EXPERIMENTAL; Interventions: Other: multi-component intervention | Arm Label: usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Intervention Type: OTHER; Name: multi-component intervention; Assigned to Arm(s): PND-MCI | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): usual care
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: telephone depression care management | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: telephone depression care management; Assigned to Arm(s): 1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Clinical Trial for the Treatment of Postnatal Depression
Brief Summary: A randomized clinical trial was carried out at primary care level in Santiago, Chile to investigate a combined treatment for women suffering post-natal depression and preventing the adverse consequences of this illness on infant's growth and development.


Options:
A: Arm Label: 1 (Placebo); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Clinical management, Behavioral: Mothercrafting | Arm Label: 2 (Sertraline); Type: ACTIVE_COMPARATOR; Interventions: Drug: Sertraline, Behavioral: Clinical management, Behavioral: Mothercrafting | Arm Label: 3 (IPT); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Interpersonal psychotherapy (IPT) | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): 2 (Sertraline) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1 (Placebo) | Intervention Type: BEHAVIORAL; Name: Interpersonal psychotherapy (IPT); Assigned to Arm(s): 3 (IPT) | Intervention Type: BEHAVIORAL; Name: Clinical management; Assigned to Arm(s): 1 (Placebo), 2 (Sertraline) | Intervention Type: BEHAVIORAL; Name: Mothercrafting; Assigned to Arm(s): 1 (Placebo), 2 (Sertraline)
B: Arm Label: TAU; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: TAU | Arm Label: DCM; Type: EXPERIMENTAL; Interventions: Behavioral: Care Management for Postpartum Depression | Intervention Type: BEHAVIORAL; Name: Care Management for Postpartum Depression; Assigned to Arm(s): DCM | Intervention Type: BEHAVIORAL; Name: TAU; Assigned to Arm(s): TAU
C: Arm Label: sertraline, psychotherapy; Type: EXPERIMENTAL; Interventions: Drug: Sertraline, Other: psychotherapy | Arm Label: placebo, psychotherapy; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo, Other: psychotherapy | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): sertraline, psychotherapy | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo, psychotherapy | Intervention Type: OTHER; Name: psychotherapy; Assigned to Arm(s): placebo, psychotherapy, sertraline, psychotherapy
D: Arm Label: PND-MCI; Type: EXPERIMENTAL; Interventions: Other: multi-component intervention | Arm Label: usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Intervention Type: OTHER; Name: multi-component intervention; Assigned to Arm(s): PND-MCI | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): usual care

Answer: D